Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NV106
- Development stage
- Discontinued
- Lead developer
- NanoValent Pharmaceuticals
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NV106 is a preclinical-stage nano-antibody drug conjugate (nADC) developed by NanoValent Pharmaceuticals for the treatment of glioblastoma (GBM). The drug utilizes the proprietary Hybrid Polymerized Liposomal Nanoparticle (HPLN) platform to create Targeted NanoSpheres (TNS) that target B7-H3 (CD276), a protein overexpressed in various solid tumors. NV106 encapsulates temozolomide, a DNA alkylating agent, allowing for targeted delivery to tumor cells while minimizing systemic toxicity. Although it was a key part of NanoValent's pipeline for B7-H3-positive malignancies, recent reports indicate its development has been discontinued.
- Other names
- NV-106NV106NV 106
02
Targets
DNAB7-H3
Beyond the preview
Go deeper on NV106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NV106.